Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment
Status:
Completed
Trial end date:
2017-10-02
Target enrollment:
Participant gender:
Summary
Results of growth factors indicate that Bone Morphogenetic Proteins (BMP) have an exceptional
ability to stimulate different characteristics of mesenchymale cells to osseous cells. Local
application of BMP results in an increase of osseous tissue regardless of the location of the
growth factor.
5 years clinical studies show that BMP's can stimulate an increase of osseous tissue and
improve clinical results when autologous bone graft is reduced or removed.
The purpose of this study is to examine whether recombinant growth factor BMP-2 can replace
autologous bone graft in order to stimulating ossification during transplantation of osseous
tissue.
Phase:
Phase 1
Details
Lead Sponsor:
Northern Orthopaedic Division, Denmark
Collaborators:
Center for Clinical and Basic Research (CCBR A/S). Medtronic